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Cu redoxAmyloid-β peptide (Aβ) is believed to be an important biomarker for the early diagnosis of Alzheimer’s
disease. Therefore, practical and reliable methods to assay Aβ levels have been coveted. In this study, a
rapid, sensitive, and selective electrochemical method for Aβ(1–40) detection using Cu2+ redox cycling
on peptide-modiﬁed gold electrodes was developed. A 19-residue peptide that can promote Aβ
ﬁbrillization (AFPP) was immobilized onto a gold electrode. After incubating an Aβ solution with the mod-
iﬁed electrode for 1 h, a Cu2+ solution was added and cyclic voltammetry measurements were conducted.
The voltammetric response was found to be proportional to the Aβ(1–40) concentration in the 0.1–5 μM
range, and a detection limit of 18 nM was achieved. Washing with sodium hydroxide and ethylenedi-
aminetetraacetate solutions easily reinitialized the modiﬁed electrode. Results obtained using the
reinitialized electrode showed good reproducibility. Furthermore, when another amyloidogenic and
Cu2+-binding protein amylin was used as the target, no voltammetric response was observed. These re-
sults indicate that the AFPP-modiﬁed electrode provides a promising, label-free, sensitive, selective,
cost-effective, and easy method for the quantiﬁcation of Aβ.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Alzheimer’s disease (AD) is the most common neurodegenerative
disease. It is characterized by progressive memory loss and cognitive
decline, as well as breakdown of social skills and emotional instability,
primarily among elderly adults [39]. The number of people with AD is
currently estimated to be 26 million; this number is predicted to be
more than 100 million worldwide by 2050 [29]. However, no treat-
ments that arrest or reverse AD are available to date, and only a few
medicines can retard or alleviate progression of the disease [7,13,36].
Moreover, clinical diagnosis of AD relies largely on documentingmental
decline, and deﬁnitive conﬁrmation of the disease can be obtained only
by postmortem examination of brain tissues for the amyloid plaques and
neuroﬁbrillary tangles that are the hallmark histopathological features
of AD [21].
Amyloid-β peptide (Aβ), a 39–43 amino acid peptide that is pro-
teolytically cleaved from the membrane-bound amyloid precursor. This is an open access article underprotein, is the major constituent of amyloid plaques and is the
most suspicious factor responsible for the progression of AD [14].
Since Aβ biomarker abnormalities precede other neurodegenerative
biomarker abnormalities before symptoms of overt dementia have
appeared, Aβ in bodily ﬂuids [e.g., cerebrospinal ﬂuid (CSF), blood,
and plasma] is considered a promising biomarker for the early diag-
nosis of AD [17,33]. Currently, clinical practice in AD diagnostics is
based upon the detection of Aβ with a sandwich enzyme-linked im-
munosorbent assay (ELISA) [28,38]. Although sandwich ELISA is re-
liable and highly sensitive, it requires a laborious procedure and a
relatively expensive enzyme-linked antibody for Aβ. It has been
pointed out that such a procedure is not suitable for early diagnos-
tics of AD [30]. Over the past decade, therefore, there have been
several advances in the development of sensitive, quantitative,
and rapid methods for the detection of Aβ, such as surface plasmon
resonance [11,12,42,48], quartz crystal microbalance (QCM) [30,31,
32], capillary electrophoresis [34], resonance light scattering [45],
gold nanoparticle immunoassay [10,46], ﬂuorescence [9], and elec-
trochemistry [19,25,26]. Most of these methods, however, require
expensive and complicated apparatus. In anticipation of the aging
of society, there is a growing need for the development of detection
methods suitable for the early diagnosis of AD.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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quantitative, and cost-effective method for the detection of Aβ. As
pointed out in the literature [19,27], use of electrochemical biosensors
is one of the most realistic candidates for achieving this end. In the
course of our study on the interaction between Cu2+ and Aβ, we discov-
ered a 19-residue peptide that can accelerate the ﬁbrillization of Aβ,
which we call AFPP (amyloid-β ﬁbrillization promoting peptide). We
have now prepared N-cysteinyl AFPP (AFPPcys) and immobilized it on
a Au electrode in an attempt to accumulate Aβ(1–40) on it and to quan-
tify the deposited Aβ(1–40). After incubation of Aβ(1–40) with the
AFPPcys-modiﬁed electrode for half an hour, we added Cu2+ to the so-
lution and allowed it to bind. We then washed away the free Cu2+ and
carried out cyclic voltammetry (CV)measurements. The results demon-
strated that the peak current and peak area are proportional to the con-
centration of Aβ(1–40) in the range of 0.1–5 μM. When amylin or islet
amyloid polypeptide, another amyloid ﬁbril forming polypeptide that
can bind to Cu2+ [22], was used as the target instead of Aβ(1–40), no
voltammetric response was observed. In addition, the AFPPcys-
modiﬁed Au electrode could be reinitialized simply by washing out
the deposited Aβ(1–40) and Cu2+ with NaOH and EDTA solutions. The
reused electrode demonstrated good reproducibility. These results indi-
cate that this promising electrochemicalmethod provides simple, rapid,
selective, and cost-effective quantiﬁcation of Aβ, although the current
sensitivity does not reach the concentration of Aβ found in bodily ﬂuids
such as CSF and plasma.
2. Materials and methods
2.1. Chemicals and reagents
Lyophilized amyloid-β peptide (1–40, human; 4307-v) and
amylin (human; 4219-v) were purchased from Peptide Institute
(Osaka, Japan). 1,1,1,3,3,3-Hexaﬂuoro-2-propanol (HFIP) and N-
ethylmorpholine (EM) were purchased from Wako Pure Chemical
Industries (Osaka, Japan). Thioﬂavin T was obtained from Sigma–
Aldrich Co. LLC. (St. Louis, MO, USA). Ethylenediamine-N,N,N′,N′-
tetraacetic acid, disodium salt, dihydrate (EDTA) was obtained
from Dojindo Laboratories (Kumamoto, Japan). All Fmoc (Fmoc,
ﬂuoren-9-ylmethoxycarbonyl) amino acid derivatives were pur-
chased from Watanabe Chemical Industries, Ltd. (Hiroshima,
Japan). Other chemicals used in this study were commercial prod-
ucts and were used without further puriﬁcation unless otherwise
indicated.
AFPP, DAEFRHDKLVFFYEVHHQK, and AFPPcys, CDAEFRHDKLV
FFYEVHHQK, were synthesized using the Fmoc solid-phase method [6]
with O-(7-aza-1H-benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium
hexaﬂuorophosphate (HATU) and 1-hydroxy-1H-benzotriazole, anhy-
drous (HOBT) as coupling reagents. The peptides were puriﬁed by
reversed-phase high performance liquid chromatography (HPLC) using
an Atlantis™ column (dC18, 5 μm, 4.6 × 150mm,Waters,MA, USA) eluted
at 0.1 mL/min. The ﬁnal products were characterized by analytical HPLC
and matrix assisted laser desorption ionization time-of-ﬂight (MALDI-
TOF) mass spectrometry.
2.2. Preparation of Aβ(1–40) and amylin solution
Aβ(1–40) and amylin were initially incubated in HFIP (1 mg/mL) at
room temperature for 24 h [22,34]. The HFIP was evaporated under a
gentle stream of N2, and the resulting clear peptide ﬁlm was stored at
−80 °C. Prior to use, the dried peptides were warmed to room temper-
ature, dissolved in Milli-Q water (Millipore Corp., Milford, MA, USA),
and then centrifuged at 4 °C (approximately 20,000×g, 10 min) to re-
move aggregates that may have formed. Eighty percent of each super-
natant was used as a stock solution. The concentrations of the stock
solutions were determined using a JASCO V-670 spectrophotometer
(Tokyo, Japan) with a tyrosine extinction coefﬁcient of 1410 M−1 cm−1 at 276 nm. The stock solutions were diluted to the desired concentra-
tion with EM buffer (20 mM EM + 150 mM NaCl, pH 7.0) or Tris/HCl
buffer (50 mM Tris + 150 mM NaCl, pH 7.0) before use.
2.3. Thioﬂavin T ﬂuorescence analysis
The promotion of Aβ(1–40) ﬁbrillization was measured using
thioﬂavin T (ThT) ﬂuorescence, which has been widely adopted for
evaluating the formation of amyloid ﬁbrils [23,24]. ThTwas freshly pre-
pared as a 5mMstock in EM(pH 7.0) and added to each test sample to a
ﬁnal concentration of 50 μM. Each sample was prepared in a 96-well
plate and shaken for 10 s prior to each measurement. Fluorescence
spectra were measured at 37 °C using a Fluoroskan Ascent FL spectro-
photometer (Thermo Scientiﬁc Inc., MA, USA). Fluorescence measure-
ments were carried out using an excitation wavelength of 430 nm and
an emission wavelength of 485 nm.
2.4. Immobilization of N-cysteinyl β-amyloid ﬁbrillization promoting pep-
tide on a Au electrode
The Au EQCM electrode (5.1 mm in diameter; #010226) was pur-
chased fromALS Co., Ltd. (Tokyo, Japan) andwashedwith piranha solu-
tion (H2O2:H2SO4 = 1:3). An AFPPcys-modiﬁed electrode was formed
by casting 400 μL of a 50 μM solution of AFPPcys in EM buffer onto the
electrode. After a 1 h incubation at 25 °C, 4 μL of 1 M NaOH solution
was added to remove aggregates that may have formed on the
immobilized AFPPcys. Then, the electrode was rinsed with Milli-Q
water. The quantity of immobilized AFPPcys was estimated using
Sauerbrey equation:
ΔF ¼ 2Δmnf 20=ðA
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
μqρq
p Þ
where ΔF is the oscillation frequency, f0 is the resonant frequency, A is
the piezoelectric area, μq is the density modulus of quartz, and ρq is
the shear modulus of quartz.
(Caution! Piranha solution is hazardous and highly reactive. It may ex-
plode on contact with organic solvents. It should be treated with great
care.)
2.5. Electrochemical detection of Aβ
For the assay, 400 μL of Aβ(1–40) EM solution was incubated with
the AFPPcys-modiﬁed electrode for 1 h at 37 °C. After washing with
Tris/HCl buffer to remove non-deposited Aβ(1–40), 200 μM of CuCl2
in Tris/HCl buffer (400 μL, pH 7.0)was added. This solutionwas incubat-
edwith the electrode for 10min at room temperature to allow the Cu2+
to bind to the deposited Aβ(1–40). The reason for changing the buffer
was to avoid the precipitation of Cu(OH)2 that occurs when EM is
used as solvent at pH 7.0. After removing free Cu2+with Tris/HCl buffer,
we carried out cyclic voltammetry experiments on an ALS 440B electro-
chemical analyzer (Tokyo, Japan) using Pt wire as the counter electrode
and Ag/AgCl as the reference electrode.
2.6. Reinitialization of the N-cysteinyl β-amyloid ﬁbrillization promoting
peptide-modiﬁed electrode
To check the reusability of the electrode, we attempted to reinitialize
the used electrode. After CV measurements, the electrode was washed
with Milli-Q water and then with 400 μL of 200 μM EDTA in Tris/HCl
for 10 min at room temperature to remove the Cu2+. Finally, the elec-
trode was washed with a 10 mM NaOH solution for 10 min at room
temperature.
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3.1. Acceleration of amyloid ﬁbril formation by amyloid-β ﬁbrillization pro-
moting peptide
To test the effect of AFPP on the aggregation of Aβ(1–40), we ex-
plored the aggregation kinetics of Aβ(1–40) in the presence of AFPP
using ThT ﬂuorescence (Fig. 1). An increase in ThT ﬂuorescence at
483 nm is a common means of monitoring the stacked β-sheets of am-
yloid ﬁbrils in solution. Because other types of aggregates that lack the
cross-β-sheet structure characteristic of amyloid ﬁbrils do not increase
its ﬂuorescence, ThT ﬂuorescence is a useful speciﬁc marker of amyloid
formation [23,24]. No substantial increase in ThT ﬂuorescence was ob-
served when only Aβ(1–40) (Fig. 1A: ■) or only AFPP (Fig. 1A: ●)
was present. When AFPP was mixed with Aβ(1–40), a rapid increase
in ThT ﬂuorescence was observed (Fig. 1A: ▴). The solubility of
Aβ(1–40) at neutral pH has been reported to be up to 15.5 μM [5,41,
43]. Even at higher concentrations, amyloidﬁbril formation is common-
ly preceded by a lag phase [15]. Therefore, the results clearly show that
AFPP efﬁciently accelerates amyloid ﬁbril formation.
To immobilize AFPP onto a Au electrode, we prepared AFPPcys,
which has an additional cysteine residue at the N-terminus of AFPP. De-
spite the additional cysteine residue, AFPPcys showed essentially the
same acceleration of amyloid formation seen with AFPP (Fig. 1B).3.2. Preparation of an N-cysteinyl β-amyloid ﬁbrillization promoting
peptide-modiﬁed Au electrode
AFPPcys was immobilized onto a Au electrode using the thiol
group of the cysteine at its N-terminus. The Au electrode was im-
mersed in 400 μL of a 50 μM AFPPcys EM solution for 1 h at 25 °C.
The immobilization process was monitored with QCM (Fig. S1).
The QCM frequency decreased soon after the addition of AFPPcys
and reached ΔF = −1800 Hz an hour later. Then, the electrode
was washed with NaOH solution to remove AFPPcys aggregated
on the immobilized AFPPcys, resulting in a shift of the QCM fre-
quency to −180 Hz. Using this frequency shift and the Sauerbrey
equation, the mass of the immobilized AFPPcys was estimated to
be 0.245 μg (9.68 nmol) [8,37].Fig. 1.Growth of amyloidﬁbrilsmonitored by ThTﬂuorescence in the presence or absence of (A
or AFPPcys (▴). Each sample was incubated at 37 °C in EM buffer (pH 7.0) and measured with3.3. Detection and quantiﬁcation of Aβ(1–40) by cyclic voltammetry
Because AFPPcys includes amino acid residues that are able to bind
to Cu2+, such as His, Tyr, Asp, and Glu, we carried out CVmeasurements
with the AFPPcys-modiﬁed electrode in the presence of Cu2+. A small
voltammetric response was observed (Fig. 2A; dashed line). When a
5 μMAβ(1–40) solutionwas incubatedwith theAFPPcys-modiﬁed elec-
trode for 1 h, followed by addition of a 200 μMCu2+ solution andwash-
ing to remove free Cu2+, a distinct, quasi-reversible CV response was
observed at 0.24 V vs Ag/AgCl (Fig. 2A; solid line). Similar quasi-
reversible CV responses have been reported for the Cu redox couple
with an Aβ(1–16)-immobilized Au electrode in which a cysteine resi-
due was appended to the C-terminus of Aβ(1–16) [35], and for Cu–
Aβ(1–42) [18], Cu–Aβ(1–40) [4], and Cu–Aβ(1–16) [1] solutions, al-
though the redox potential of Cu–Aβ complex observed in this study
is higher than those of Cu–Aβ complexes formed in the solution [4,
18]. This positive shift of the redox potential is probably due to the
size of aggregation. In fact, it is reported that the morphology of Aβ ag-
gregation affects the redox property of Cu–Aβ complex and the Cu com-
plex with large aggregates shows a more positive redox potential than
that with small aggregates [40]. Furthermore, a plot of the current vs.
scan rate shows a linear correlation (Fig. S2B), indicating that the fara-
daic response was from a large surface-immobilized species, i.e., a
Cu2+–Aβ(1–40) complex in large aggregates [47].
Because we succeeded in getting a well-deﬁned faradaic response
with the AFPPcys-modiﬁed electrode, we investigated the correlation
between Aβ(1–40) concentration and voltammetric response. The ab-
solute CV anodic peak current (|ip|) increased linearly with a linear in-
crease in the Aβ(1–40) concentration (Fig. S3). As demonstrated in
Fig. 2B, the integrated area of the peak shows a better linear correlation
[correlation coefﬁcient (R2) of 0.998] with the Aβ(1–40) concentration
in the range of 0.1–5 μM.
At lower Aβ(1–40) concentrations, e.g., 50 nM, a distinct
voltammetric response was obtained (Fig. S4), but these data are not
on the line. Indeed, the limit of detection (LOD), estimated by three
times the standard deviation of the blank (3σ), was 18 nM (78
ng/mL) and the limit of quantitation (LOQ), estimated from 10σ, was
180 nM. The LOD of this method is better than those of a recently pub-
lished capillary electrophoresis assay (0.5 μM Aβ(1–40)) [34] and an
electrochemical assay that detected the oxidation of Tyr at position 10) AFPP; (B) AFPPcys: 10 μMAβ (■); 10 μMAFPP or AFPPcys (●); and 5 μMAβ+5 μMAFPP
50 μM ThT. Error bars indicate standard error of the measurement for n= 3.
Fig. 2. (A) Cyclic voltammograms obtained using a AFPPcys-modifed electrode after Cu2+ loading in the absence (dashed line) or the presence (solid line) of additional 5 μM Cu2+ ion in
Tris/HCl buffer (pH 7.0). The scan rate was 50 mV/s. (B) Linear plot of the integrated area of the CV peak as a function of Aβ(1–40) concentration (0.1, 0.5, 1.0, 3.0, and 5.0 μM) using the
AFPPcys-modiﬁed electrode. Error bars indicate standard error of the measurement for n= 3.
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worse than those of other reported assays, such as a sol–gel-derived op-
tical array biosensor (2.5 ng/mL) [9], an electrochemical immunoassay
using p-aminophenol redox cycling (5 pM Aβ(1–42)) [26], a Au
nanoparticle-based dot-blot immunoassay (50 pg/mL Aβ(1–42)) [46],
and an electrochemical assay using a horseradish peroxidase-Au-
gelsolin nanoprobe (28 pM Aβ(1–40)/Aβ(1–42)) [49].
Because the Aβ(1–40) levels in CSF and plasma are reported to be
8–11.9 ng/mL and 213–290 pg/mL, respectively [28], this method
(LOD, 78 ng/mL) cannot be applied to samples of bodily ﬂuids at this
stage. The reason underlying the low sensitivity of this method is that
the quantity of Aβ(1–40) deposited on the AFPPcys was only 0.394%
(3.14 × 10−11 mol, 0.136 μg; 0.667 μg/cm2) of the total Aβ(1–40)
added (400 μL of 5 μMEM solution), which was estimated from the fre-
quency shift of the QCM proﬁle. Similar results were obtained using an
Aβ(1–40)-immobilized Au electrode and a QCM [32]. They succeeded in
monitoring the aggregation of Aβ(1–40) on the electrode and observed
a frequency change of −19,000 Hz, which corresponded to an 11.8
μg/cm2 mass increase [1.8% of the Aβ(1–40) added] after a 9-h incuba-
tion. Considering the incubation time and quantity of Aβ deposited,
the ability of AFPPcys to facilitate Aβ(1–40) aggregation is comparable
to or better than that of Aβ(1–40).
Further, the amount of Aβ(1–40) deposited (3.14 × 10−11 mol), es-
timated using the QCM frequency change, is consistentwith the quanti-
ty of electrons (ca. 2.8 × 10−11 mol) calculated from the integrated area
of the CV peak (2.7 μC for 5 μM Aβ(1–40) solution; Fig. 2B). It is gener-
ally accepted that there are two Cu2+ binding sites in full-length Aβ; a
high-afﬁnity binding site spanning residues 1–16 and a low-afﬁnity
binding site observed only when the peptide is extended to residue 28
or further [16]. However, as in a previous report that showed the second
Cu2+ binding site on Aβ(1–40) ﬁbrils was not created by the ﬁbrillar ar-
chitecture [20], Cu2+ binds in a 1:1 ratio to Aβ(1–40) in the amyloid ﬁ-
bril deposited on the AFPPcys-modifed electrode.
3.4. Selectivity of the N-cysteinyl β-amyloid ﬁbrillization promoting
peptide-modiﬁed electrode
To test the selectivity of the AFPPcys-modiﬁed electrode’s accelera-
tion of amyloid ﬁbril formation, we used amylin as a sample instead ofAβ(1–40). Amylin is a 37-amino-acid polypeptide from pancreatic
islet β-cells that forms amyloid ﬁbrils [2,3]. Amylin can also ligate
Cu2+ [22]; therefore, the properties of amylin are analogous to those
of Aβ(1–40). Fig. 3A compares the frequency changes observed during
incubation of amylin on bare and AFPPcys-modiﬁed electrodes. When
amylin was added to a bare Au electrode, a small frequency change
was observed, probably due to the reaction of the disulﬁde bond
(Cys2-Cys7) of amylin with the Au surface. In contrast, when amylin
was added to the AFPPcys-modiﬁed Au electrode, a much smaller fre-
quency change was observed, indicating that amylin does not react
with the modiﬁed electrode surface and does not deposit on the
immobilized AFPPcys. In fact, there was no signiﬁcant change in the
CV response (Fig. 3B). These results indicate that AFPP shows some se-
lectivity in its ability to accelerate the amyloid ﬁbril formation of
amyloidogenic peptides.
3.5. Reusability of N-cysteinyl β-amyloid ﬁbrillization promoting peptide-
modiﬁed electrode and reproducibility of measured results
Most of the highly sensitive assays reported to date include an anti-
body targeting Aβ that can only be used once [11,26,28,38,45,46,49]. In-
corporating expensive reagents that are essentially for single-use
increases the cost of the measurement. Because the method proposed
in this study does not use any antibodies and the AFPPcys is covalently
immobilized onto the Au electrode via a Au–S bond, the electrode is ex-
pected to be robust enough for repeated use. Fig. 4 shows the reproduc-
ibility of the voltammetric responses of the AFPPcys-modiﬁed electrode
over 5measurement-and-washing cycles. The static base current values
(−0.462 ± 0.006 μA) derived from Cu2+-AFPPcys immobilized on the
Au electrode (Fig. 4 ■) indicate that the immobilization of AFPPcys is
stable to washing with NaOH and EDTA. The anodic current obtained
after incubation with a 5-μM Aβ(1–40) solution (Fig. 4 ●) also shows
good reproducibility, with a relative standard deviation of 1.95% (n =
5), which is similar or superior to those of other assays [26,48,49].
4. Conclusions
This work demonstrated the electrochemical detection of Aβ(1–40)
at concentrations down to 0.1 μM (5 × 102 ng/mL) using an AFPPcys-
Fig. 4. Reusability of the AFPPcys-modifed electrode. The absolute anodic peak currents
observed with the AFPPcys-modiﬁed electrode after Cu2+ loading to the initialized elec-
trode (■) and to the Aβ (1–40) deposited electrode (5 μM, 1 h) (●). Data from ﬁve mea-
surement-washing cycles are shown.
Fig. 3. (A) Observed QCM response by binding of amylin to a AFPPcys-modiﬁed surface (solid line) and to a bare Au surface (dashed line). (B) Cyclic voltammograms obtained using a
AFPPcys-modiﬁed electrode after Cu2+ loading in the presence (solid line) or the absence (dashed line) of amylin in Tris/HCl buffer (pH 7.0). The scan rate was 50 mV/s.
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easily reinitializes the AFPPcys-modiﬁed electrode, which gives good,
reproducible results. This method provides rapid, simple, label-free,
quantitative, and cost-effective detection of Aβ(1–40). Although
Aβ(1–40) was chosen to establish the new assay method, our method-
ology is easily applicable to other Aβ peptides of different length, such
as Aβ(1–42) and Aβ(1–28). Unfortunately, the sensitivity of this meth-
od is insufﬁcient at present for use with levels of Aβ(1–40) found in
bodily ﬂuids, such as CSF and plasma. However, there is still room for
improvement in the electrode and sampling system. We believe that
our method will be valuable for the low-cost early diagnosis of AD
when its sensitivity is improved.
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